Do analysts prefer RFAI or MIRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, RFAI or MIRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RF Acquisition Corp II N/A N/A N/A N/A N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A

Is RFAI or MIRA more profitable?

RF Acquisition Corp II's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets RF Acquisition Corp II N/A N/A N/A MIRA Pharmaceuticals N/A -106.95% -104.18%

Do analysts prefer MIRA or UNCY?

Unicycive Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 253.77%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Unicycive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Is MIRA or UNCY more profitable?

Unicycive Therapeutics' return on equity of -91.50% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -106.95% -104.18% Unicycive Therapeutics N/A -91.50% -61.47%

Does the media prefer MIRA or UNCY?

In the previous week, Unicycive Therapeutics had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 3 mentions for Unicycive Therapeutics and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.12 beat Unicycive Therapeutics' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MIST or MIRA?

Milestone Pharmaceuticals presently has a consensus price target of $6.40, suggesting a potential upside of 428.93%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MIST or MIRA more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -288.33% -58.27% MIRA Pharmaceuticals N/A -106.95% -104.18%

Does the media refer more to MIST or MIRA?

In the previous week, Milestone Pharmaceuticals had 6 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 8 mentions for Milestone Pharmaceuticals and 2 mentions for MIRA Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.56 beat MIRA Pharmaceuticals' score of 0.12 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MIRA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AARD or MIRA?

Aardvark Therapeutics currently has a consensus price target of $15.33, suggesting a potential upside of 167.60%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aardvark Therapeutics is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.42 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, AARD or MIRA?

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A

Is AARD or MIRA more profitable?

Aardvark Therapeutics' return on equity of -71.54% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% MIRA Pharmaceuticals N/A -106.95% -104.18%

Does the media favor AARD or MIRA?

In the previous week, Aardvark Therapeutics had 22 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.12 beat Aardvark Therapeutics' score of 0.03 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MIRA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RFL or MIRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

MIRA Pharmaceuticals (MIRA) Competitors

$0.74 -0.11 (-12.94%)

As of 09/3/2026 04:00 PM Eastern

Compare

MIRA vs. RFAI, UNCY, MIST, AARD, and RFL

Should you buy MIRA Pharmaceuticals stock or one of its competitors? MIRA Pharmaceuticals's main competitors and comparable companies include RF Acquisition Corp II (RFAI), Unicycive Therapeutics (UNCY), Milestone Pharmaceuticals (MIST), Aardvark Therapeutics (AARD), and Rafael (RFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MIRA Pharmaceuticals compare to RF Acquisition Corp II?

RF Acquisition Corp II (NASDAQ:RFAI) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 39.1% of RF Acquisition Corp II shares are held by company insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 2 mentions for MIRA Pharmaceuticals and 0 mentions for RF Acquisition Corp II. MIRA Pharmaceuticals' average media sentiment score of 0.12 beat RF Acquisition Corp II's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
RF Acquisition Corp II	Neutral
MIRA Pharmaceuticals	Neutral

RF Acquisition Corp II has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

RF Acquisition Corp II's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RF Acquisition Corp II	N/A	N/A	N/A
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

Summary

MIRA Pharmaceuticals beats RF Acquisition Corp II on 6 of the 9 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Unicycive Therapeutics?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Unicycive Therapeutics' return on equity of -91.50% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MIRA Pharmaceuticals has higher earnings, but lower revenue than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
Unicycive Therapeutics	$680K	217.07	-$26.56M	-$1.75	N/A

Unicycive Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 253.77%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Unicycive Therapeutics had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 3 mentions for Unicycive Therapeutics and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.12 beat Unicycive Therapeutics' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MIRA Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MIRA Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

Summary

Unicycive Therapeutics beats MIRA Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Milestone Pharmaceuticals had 6 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 8 mentions for Milestone Pharmaceuticals and 2 mentions for MIRA Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.56 beat MIRA Pharmaceuticals' score of 0.12 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MIRA Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Milestone Pharmaceuticals presently has a consensus price target of $6.40, suggesting a potential upside of 428.93%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MIRA Pharmaceuticals' return on equity of -106.95% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

MIRA Pharmaceuticals has lower revenue, but higher earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	97.19	-$63.06M	-$0.69	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Milestone Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Summary

Milestone Pharmaceuticals beats MIRA Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

In the previous week, Aardvark Therapeutics had 22 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.12 beat Aardvark Therapeutics' score of 0.03 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	23 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MIRA Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aardvark Therapeutics has a beta of 3.74, suggesting that its stock price is 274% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Aardvark Therapeutics' return on equity of -71.54% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

Aardvark Therapeutics currently has a consensus price target of $15.33, suggesting a potential upside of 167.60%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aardvark Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aardvark Therapeutics beats MIRA Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Rafael?

Rafael (NYSE:RFL) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than Rafael. MarketBeat recorded 2 mentions for MIRA Pharmaceuticals and 0 mentions for Rafael. MIRA Pharmaceuticals' average media sentiment score of 0.12 beat Rafael's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Rafael	Neutral
MIRA Pharmaceuticals	Neutral

Rafael has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

11.3% of Rafael shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 32.9% of Rafael shares are held by insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MIRA Pharmaceuticals has lower revenue, but higher earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	141.30	-$30.52M	-$0.68	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

MIRA Pharmaceuticals has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

Summary

MIRA Pharmaceuticals beats Rafael on 9 of the 14 factors compared between the two stocks.

Get MIRA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRA vs. The Competition

Export

Metric	MIRA Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$35.70M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.60	787.27	273.29	25.38
Price / Sales	N/A	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	3.89	12.33	12.89	6.14
Net Income	-$10.44M	$2.82B	$3.47B	$349.01M
7 Day Performance	-1.40%	2.59%	0.60%	-0.27%
1 Month Performance	9.57%	6.95%	5.73%	0.68%
1 Year Performance	-46.41%	9.45%	25.35%	14.84%

MIRA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRA MIRA Pharmaceuticals	0.8753 of 5 stars	$0.74 -12.9%	N/A	-46.8%	$35.70M	N/A	N/A	2
RFAI RF Acquisition Corp II	0.5948 of 5 stars	$41.01 -4.7%	N/A	+293.8%	$143.95M	N/A	N/A	N/A
UNCY Unicycive Therapeutics	2.1566 of 5 stars	$5.07 -2.5%	$18.75 +269.8%	+23.5%	$141.20M	$680K	N/A	9	News Coverage
MIST Milestone Pharmaceuticals	2.6274 of 5 stars	$1.13 -3.0%	$6.40 +468.9%	-32.0%	$140.06M	$1.55M	N/A	30	News Coverage Analyst Forecast Gap Up
AARD Aardvark Therapeutics	2.8675 of 5 stars	$6.11 +0.2%	$15.33 +151.0%	-30.0%	$133.69M	N/A	N/A	18	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. RFAI, UNCY, MIST, AARD, and RFL

How does MIRA Pharmaceuticals compare to RF Acquisition Corp II?

Summary

How does MIRA Pharmaceuticals compare to Unicycive Therapeutics?

Summary

How does MIRA Pharmaceuticals compare to Milestone Pharmaceuticals?

Summary

How does MIRA Pharmaceuticals compare to Aardvark Therapeutics?

Summary

How does MIRA Pharmaceuticals compare to Rafael?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. RFAI, UNCY, MIST, AARD, and RFL

How does MIRA Pharmaceuticals compare to RF Acquisition Corp II?

Which has better earnings & valuation, RFAI or MIRA?

Do insiders and institutionals have more ownership in RFAI or MIRA?

Do analysts prefer RFAI or MIRA?

Does the media favor RFAI or MIRA?

Which has more risk & volatility, RFAI or MIRA?

Is RFAI or MIRA more profitable?

Summary

How does MIRA Pharmaceuticals compare to Unicycive Therapeutics?

Is MIRA or UNCY more profitable?

Do insiders & institutionals hold more shares of MIRA or UNCY?

Which has stronger earnings and valuation, MIRA or UNCY?

Do analysts prefer MIRA or UNCY?

Does the media prefer MIRA or UNCY?

Which has more volatility & risk, MIRA or UNCY?

Summary

How does MIRA Pharmaceuticals compare to Milestone Pharmaceuticals?

Does the media refer more to MIST or MIRA?

Do analysts recommend MIST or MIRA?

Is MIST or MIRA more profitable?

Which has stronger earnings & valuation, MIST or MIRA?

Do institutionals and insiders hold more shares of MIST or MIRA?

Which has more volatility & risk, MIST or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Aardvark Therapeutics?

Which has preferable valuation & earnings, AARD or MIRA?

Does the media favor AARD or MIRA?

Do institutionals & insiders have more ownership in AARD or MIRA?

Which has more risk and volatility, AARD or MIRA?

Is AARD or MIRA more profitable?

Do analysts recommend AARD or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Rafael?

Does the media favor RFL or MIRA?

Which has more volatility & risk, RFL or MIRA?

Do insiders and institutionals have more ownership in RFL or MIRA?

Do analysts recommend RFL or MIRA?

Which has better valuation and earnings, RFL or MIRA?

Is RFL or MIRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools